Covaxin Approved For Emergency Use In 218-Year-Olds
Please Subscribe and Get Daily Updates in Your Inbox!!!
Highlights
♦ In September, the phase 2 and 3 trials of Covaxin happed, and reports were submitted to the Drugs and Comptroller General of India (DCGI) in October.
♦ The trials suggested that the safety and immunity of the Covaxin are almost as same in children aged 2-18 years, as it is in adults above 18-years of age.
♦ The Covaxin, also known as BBV15, is an inactivated virus-based COVID-19 vaccine developed by Bharat Biotech with the Indian Council of Medical Research (ICMR).
♦ Covaixn was developed using a traditional Technology where the National Institute of Virology isolated a sample of SARS-CoV-2, India, to grow large quantities of the virus using the Vero cells.
♦ The viruses were soaked in beta-propiolactone to deactivate them by binding to their genes. Resulting inactivated viruses were then mixed with aluminium-based adjuvant Alhydroxiquim-II.
